Non WHO Reference Material
Anti-meningococcal serogroup Y monoclonal antibody
NIBSC code: 12/284
Instructions for use
(Version 2.0, Dated 12/06/2019)

This material is not for in vitro diagnostic use.

1. INTENDED USE
For use as a typing reagent

2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.

Antibody is of murine origin. The material contains materials of bovine origin that is certified to be obtained from animals taken from a closed herd in the female line since 1980, in which no animal has been clinically suspected of having BSE and which has not been fed rations containing ruminant derived protein during that period. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE
Units of activity have not been assigned to this material. However, when used for whole-cell dot blot, a dilution of 1 in 50 of the reconstituted material is recommended. Refer to Table on page 2.

4. CONTENTS
Country of origin of biological material: United Kingdom.
Ascitic fluid purified by 50% Ammonium sulfate cut then DEAE ion exchange in to a final buffer of 20mM Na phosphate/150mM NaCl. Purified ascites were diluted with RPMI tissue culture medium and 25% fetal calf serum before freeze-drying.

5. STORAGE
Store freeze-dried ampoules and reconstituted aliquots at -20°C. Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufacturers instructions provided with the ampoule breaker.

7. USE OF MATERIAL
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution.
The entire content of the ampoule should be rehydrated with 1 ml of sterile water.

8. STABILITY
Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.
The recommended working concentrations were correct at the time of manufacture - no information is available on long term stability. Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

9. REFERENCES
N/A

10. ACKNOWLEDGEMENTS
We are grateful to Pfizer Vaccine Research, USA for providing purified ascitic fluid from hybridoma PFEmY.

11. FURTHER INFORMATION
Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/jctlm/
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008:</td>
</tr>
<tr>
<td>Not applicable or not classified</td>
</tr>
<tr>
<td>Physical appearance:</td>
</tr>
<tr>
<td>Freeze-dried powder</td>
</tr>
<tr>
<td>Stable: Yes</td>
</tr>
<tr>
<td>Oxidising: No</td>
</tr>
<tr>
<td>Hygroscopic: No</td>
</tr>
<tr>
<td>Irritating: No</td>
</tr>
<tr>
<td>Flammable: No</td>
</tr>
<tr>
<td>Handling: See caution, Section 2</td>
</tr>
<tr>
<td>Other (specify): N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Toxicological properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effects of inhalation: Not established, avoid inhalation</td>
</tr>
<tr>
<td>Effects of ingestion: Not established, avoid ingestion</td>
</tr>
<tr>
<td>Effects of skin absorption: Not established, avoid contact with skin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Suggested First Aid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation: Seek medical advice</td>
</tr>
<tr>
<td>Ingestion: Seek medical advice</td>
</tr>
<tr>
<td>Contact with eyes: Wash with copious amounts of water. Seek medical advice</td>
</tr>
<tr>
<td>Contact with skin: Wash thoroughly with water.</td>
</tr>
</tbody>
</table>
### Action on Spillage and Method of Disposal

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

### 15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents. Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

### 16. INFORMATION FOR CUSTOMS USE ONLY

<table>
<thead>
<tr>
<th>Country of origin for customs purposes*: United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net weight: 4.5 g</td>
</tr>
<tr>
<td>Toxicity Statement: Toxicity not assessed</td>
</tr>
<tr>
<td>Veterinary certificate or other statement if applicable. Attached: No</td>
</tr>
</tbody>
</table>

### Explanation of numbering system:

1. Source of mAb: The laboratory where the hybridoma was isolated and their hybridoma clone designation.
2. NIBSC hybridoma stock number: this number was assigned at NIBSC when we received the hybridoma cells and is for NIBSC stock control only.
3. Determined by S.Gray Manchester Meningococcal Reference Unit

<table>
<thead>
<tr>
<th>Specificity</th>
<th>Source of mAb¹</th>
<th>NIBSC hybridoma stock number²</th>
<th>Isotype</th>
<th>Resuspension</th>
<th>Concentration of reconstituted stock to use in dot-blot ³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neisseria meningitidis serogroup Y polysaccharide</td>
<td>Pfizer Vaccine Research, USA. PFEMnY</td>
<td>N/A</td>
<td>Mouse IgG1, kappa</td>
<td>Each Din Ampoule should be resuspended with 1ml sterile distilled water</td>
<td>1 in 50</td>
</tr>
</tbody>
</table>

---

¹ Source of mAb: The laboratory where the hybridoma was isolated and their hybridoma clone designation.
² NIBSC hybridoma stock number: this number was assigned at NIBSC when we received the hybridoma cells and is for NIBSC stock control only.
³ Determined by S.Gray Manchester Meningococcal Reference Unit